September 27th 2024
The agency is recommending that the market authorization for Oxbryta (voxelotor) be suspended so that emerging data may be reviewed.
EMA Says No Evidence for Link between Type 2 Diabetes Drugs and Suicidal Tendencies
April 12th 2024The agency’s risk assessment committee has concluded that available evidence has not been found that supports a causal association between glucagon-like peptide-1 receptor agonists and self-harming thoughts and actions.